Amgen Inc. (AMGN) to Issue Quarterly Dividend of $2.52 on June 5th

Amgen Inc. (NASDAQ:AMGN) declared a quarterly dividend on Wednesday, March 4th. Stockholders of record on Friday, May 15th will be paid a dividend of 2.52 per share by the medical research company on Friday, June 5th. This represents a c) dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, May 15th.

Amgen has raised its dividend by an average of 0.1%per year over the last three years and has increased its dividend annually for the last 14 consecutive years. Amgen has a dividend payout ratio of 46.8% meaning its dividend is sufficiently covered by earnings. Research analysts expect Amgen to earn $23.49 per share next year, which means the company should continue to be able to cover its $10.08 annual dividend with an expected future payout ratio of 42.9%.

Amgen Stock Up 2.0%

Shares of AMGN stock opened at $336.29 on Wednesday. The stock’s 50-day simple moving average is $352.03 and its 200-day simple moving average is $342.49. The company has a debt-to-equity ratio of 5.65, a quick ratio of 1.01 and a current ratio of 1.26. The firm has a market capitalization of $181.49 billion, a PE ratio of 23.40, a P/E/G ratio of 3.31 and a beta of 0.44. Amgen has a fifty-two week low of $261.43 and a fifty-two week high of $391.29.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings data on Thursday, April 30th. The medical research company reported $5.15 earnings per share for the quarter, beating analysts’ consensus estimates of $4.77 by $0.38. The business had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The company’s revenue was up 5.8% on a year-over-year basis. During the same period in the prior year, the company earned $4.90 earnings per share. Amgen has set its FY 2026 guidance at 21.700-23.100 EPS. Equities analysts expect that Amgen will post 22.36 earnings per share for the current year.

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the firm’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $323.73, for a total value of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company’s stock, valued at approximately $2,269,023.57. This trade represents a 15.00% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders own 0.85% of the company’s stock.

Institutional Trading of Amgen

Several institutional investors have recently modified their holdings of AMGN. Norges Bank acquired a new stake in shares of Amgen in the fourth quarter valued at about $2,164,162,000. Capital World Investors boosted its stake in shares of Amgen by 22.9% in the fourth quarter. Capital World Investors now owns 23,097,711 shares of the medical research company’s stock worth $7,560,249,000 after acquiring an additional 4,302,237 shares during the last quarter. State Street Corp boosted its stake in shares of Amgen by 4.4% in the fourth quarter. State Street Corp now owns 30,591,403 shares of the medical research company’s stock worth $10,012,872,000 after acquiring an additional 1,287,310 shares during the last quarter. Geode Capital Management LLC boosted its stake in shares of Amgen by 7.8% in the fourth quarter. Geode Capital Management LLC now owns 14,303,294 shares of the medical research company’s stock worth $4,665,822,000 after acquiring an additional 1,035,779 shares during the last quarter. Finally, Amundi boosted its stake in shares of Amgen by 41.1% in the fourth quarter. Amundi now owns 3,396,945 shares of the medical research company’s stock worth $1,111,854,000 after acquiring an additional 988,856 shares during the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.